Wolfe starts Bruker at Outperform

Wolfe Research initiated coverage of Bruker with an Outperform rating and $80 price target. The combination of solid visibility on generating mid-single-digit/high-single-digit 2024 revenue growth, unique portfolio positioning to capitalize on durable secular tailwinds, a premier track record of scientific innovation, and a discount relative valuation position Bruker to Outperform, the analyst tells investors in a research note.